View Item 

Show simple item record

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report

dc.contributor.authorSchriber, Jeffrey R.
dc.contributor.authorHari, Parameswaran N.
dc.contributor.authorAhn, Kwang Woo
dc.contributor.authorFei, Mingwei
dc.contributor.authorCosta, Luciano J.
dc.contributor.authorKharfan‐dabaja, Mohamad A.
dc.contributor.authorAngel‐diaz, Miguel
dc.contributor.authorGale, Robert P.
dc.contributor.authorGanguly, Siddharatha
dc.contributor.authorGirnius, Saulius K.
dc.contributor.authorHashmi, Shahrukh
dc.contributor.authorPawarode, Attaphol
dc.contributor.authorVesole, David H.
dc.contributor.authorWiernik, Peter H.
dc.contributor.authorWirk, Baldeep M.
dc.contributor.authorMarks, David I.
dc.contributor.authorNishihori, Taiga
dc.contributor.authorOlsson, Richard F.
dc.contributor.authorUsmani, Saad Z.
dc.contributor.authorMark, Tomer M.
dc.contributor.authorNieto, Yago L.
dc.contributor.authorD’Souza, Anita
dc.date.accessioned2017-10-05T18:16:24Z
dc.date.available2018-11-01T16:42:00Zen
dc.date.issued2017-08-15
dc.identifier.citationSchriber, Jeffrey R.; Hari, Parameswaran N.; Ahn, Kwang Woo; Fei, Mingwei; Costa, Luciano J.; Kharfan‐dabaja, Mohamad A. ; Angel‐diaz, Miguel ; Gale, Robert P.; Ganguly, Siddharatha; Girnius, Saulius K.; Hashmi, Shahrukh; Pawarode, Attaphol; Vesole, David H.; Wiernik, Peter H.; Wirk, Baldeep M.; Marks, David I.; Nishihori, Taiga; Olsson, Richard F.; Usmani, Saad Z.; Mark, Tomer M.; Nieto, Yago L.; D’Souza, Anita (2017). "Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report." Cancer 123(16): 3141-3149.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/138212
dc.publisherWiley Periodicals, Inc.
dc.publisherNCCN
dc.subject.otherHispanic
dc.subject.otherblacks
dc.subject.othertransplantation utilization
dc.subject.othermyeloma
dc.titleHispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138212/1/cncr30747_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138212/2/cncr30747.pdf
dc.identifier.doi10.1002/cncr.30747
dc.identifier.sourceCancer
dc.identifier.citedreferencePalumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014; 371: 895 â 905.
dc.identifier.citedreferenceAttal M, Lauwersâ Cances V, Hulin C, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 trial) [abstract 391]. Paper presented at: 57th Annual Meeting and Exposition of the American Society of Hematology; December 5â 8, 2015; Orlando, FL.
dc.identifier.citedreferenceCosta LJ, Huang JX, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant. 2015; 21: 701 â 706.
dc.identifier.citedreferenceWarren JL, Harlan LC, Stevens J, Little RF, Abel GA. Multiple myeloma treatment transformed: a populationâ based study of changes in initial management approaches in the United States. J Clin Oncol. 2013; 31: 1984 â 1989.
dc.identifier.citedreferenceAlâ Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socioâ geoâ demographic factors in the era of novel agents. Am J Hematol. 2014; 89: 825 â 830.
dc.identifier.citedreferenceNational Comprehensive Cancer Network (NCCN). NCCN Guidelines, Version 1.2017: Multiple Myeloma. Fort Washington, PA: NCCN; 2016.
dc.identifier.citedreferenceGay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015; 16: 1617 â 1629.
dc.identifier.citedreferenceCavo M, Palumbo A, Zweegman S, et al. Upfront autologous stem cell transplantation (ASCT) versus novel agentâ based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial) [abstract]. J Clin Oncol. 2016; 34 ( suppl ). Abstract 8000.
dc.identifier.citedreferenceUnited States Census Bureau. United States Census 2010. Available at: https://www.census.gov/2010census/. Accessed November 1, 2016.
dc.identifier.citedreferenceCosta LJ, Zhang MJ, Zhong X, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013; 19: 1615 â 1624.
dc.identifier.citedreferenceCosta LJ, Hari PN, Kumar SK. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma. 2016; 57: 2827 â 2832.
dc.identifier.citedreferenceSchriber J, Bean C, Simpson E, et al. No differences in stem cell transplantation utilization rates (STUR) by ethnicity after referral to a transplant center for multiple myeloma (MM): implications for improving STUR rates in minorities. Biol Blood Marrow Transplant. 2017; 23 ( suppl ): S270 â S271.
dc.identifier.citedreferenceMayberry RM, Mili F, Ofili E. Racial and ethnic differences in access to medical care. Med Care Res Rev. 2000; 57 ( suppl 1 ): 108 â 145.
dc.identifier.citedreferenceInstitute of Medicine (US) Committee on Understanding and Eliminating Racial Disparities in Health Care; Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC. National Academies Press; 2003.
dc.identifier.citedreferenceFiala MA, Finney JD, Stockerlâ Goldstein KE, et al. Re: disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant. 2015; 21: 1153 â 1154.
dc.identifier.citedreferenceBhatnagar V, Wu Y, Goloubeva OG, et al. Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study. Cancer. 2015; 121: 1064 â 1070.
dc.identifier.citedreferenceSurveillance, Epidemiology, and End Results (SEER) Program ( www/seer/cancer/gov ). SEER*Stat Database: Incidenceâ SEER 18 Regs Research Data, Nov 2015 submission (2000â 2013)â Linked To County Attributesâ Total U.S., 1969â 2014 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. Available at: http://seer.cancer.gov/data/.
dc.identifier.citedreferenceGay F, Cerrato C, Hajek R, et al. Impact of autologous transplantation vs chemotherapy plus lenalidomide in newly diagnosed myeloma according to patient prognosis: results of a pooled analysis of 2 phase III trials [abstract]. Blood. 2014; 124: 198. Accessed November 1, 2016.
dc.identifier.citedreferenceAilawadhi S, Aldoss IT, Yang D, et al. Outcome disparities in multiple myeloma: a SEERâ based comparative analysis of ethnic subgroups. Br J Haematol. 2012; 158: 91 â 98.
dc.identifier.citedreferencePulte D, Redaniel MT, Brenner H, Jansen L, Jeffreys M. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity. Leuk Lymphoma. 2014; 55: 1083 â 1089.
dc.identifier.citedreferenceSurveillance Research Program, National Cancer Institute. SEER*Stat software ( seer.cancer.gov/seerstat ) version 8.3.2. Bethesda, MD: National Cancer Institute; 2017.
dc.identifier.citedreferenceJoshua TV, Rizzo JD, Zhang MJ, et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010; 116: 3469 â 3476.
dc.identifier.citedreferenceHari PN, Majhail NS, Zhang MJ, et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010; 16: 395 â 402.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr30747_am.pdf
Size:
466.4KB
Format:
PDF
View/Open
Name:
cncr30747.pdf
Size:
216.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.